Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies
The treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis
https://www.cell.com/med/fulltext/S2666-6340(24)00114-4
The two-week ceasefire agreed upon on Tuesday between the USA, Israel, and Iran marks the preliminary end of an escalation that has gripped the Middle East since February 2026.
A winter storm with up to 15 centimeters of new snow has plunged Germany into traffic chaos. Highways and country roads are blocked in many places, accidents are increasing, and the…
Dementia is a progressive brain disease that leads to a decline in cognitive abilities. It affects memory, thinking, orientation, and the…
